Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/19192| Title: | Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study. | Austin Authors: | Gannan, Emma;Khoo, Jeremy;Nightingale, Sophie;Suhardja, Thomas Surya;Lippey, Jocelyn;Keane, Holly;Tan, Kian Jin;Clouston, David;Gorelik, Alexandra;Mann, Gregory Bruce | Affiliation: | Department of Surgery, Austin Health, Heidelberg, Victoria, Australia Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia Department of Surgery, The Royal Melbourne Hospital, Parkville, Victoria, Australia Department of Surgery, The Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Department of Surgery, Monash Medical Centre, Clayton, Victoria, Australia Department of Surgery, The Alfred Hospital, Melbourne, Victoria, Australia Department of Surgery, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia Focus Pathology, East Melbourne, Victoria, Australia Melbourne EpiCentre, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia The Breast Service, The Royal Melbourne Hospital & The Royal Women's Hospital, Parkville, Victoria, Australia |
Issue Date: | Jul-2016 | Date: | 2016-04-20 | Publication information: | The breast journal 2016; 22(4): 413-419 | Abstract: | To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1-2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009-2010 to 2011-2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009-2010 and 22.2% in 2011-2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011-eligible and -ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/19192 | DOI: | 10.1111/tbj.12595 | Journal: | The breast journal | PubMed URL: | 27095381 | Type: | Journal Article | Subjects: | ACOSOG Z0011 trial axillary lymph node dissection breast cancer sentinel lymph node biopsy |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.